Technically Speakin...
Health Care: Drugs
Durect Corporation (DRRX: NASDAQ)
$0.82 -0.01 | -1.10%
06/04/12 - 09:38 AM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 8.90M | 10.44M | 8.29M | 29.44M |
| Receivables | 3.45M | 3.72M | 1.70M | 4.06M |
| Inventories | 3.25M | 2.84M | 2.80M | 3.47M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 37.30M | 54.84M | 47.05M | 60.28M |
| Property, Plant & Equipment, Gross | 22.83M | 24.16M | 24.00M | 23.70M |
| Accumulated Depreciation & Depletion | 19.71M | 22.39M | 20.19M | 17.73M |
| Property, Plant & Equipment, Net | 3.12M | 1.78M | 3.81M | 5.97M |
| Intangibles | 53.00K | 71.00K | 108.00K | 157.00K |
| Other Non-Current Assets | 2.32M | 4.47M | 783.00K | 2.06M |
| Total Non-Current Assets | 11.90M | 12.72M | 11.10M | 14.59M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 49.20M | 67.56M | 58.15M | 74.87M |
| Accounts Payable | 1.27M | 981.00K | 1.02M | 1.02M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 1.36M | 2.32M | 1.20M | 1.43M |
| Total Current Liabilities | 14.89M | 17.91M | 12.26M | 16.88M |
| Long Term Debt | 0.00 | 0.00 | 508.00K | 656.00K |
| Deferred Income Taxes | 30.09M | 34.85M | 17.54M | 19.77M |
| Other Non-Current Liabilities | 738.00K | 315.00K | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 30.83M | 35.16M | 18.05M | 20.43M |
| Total Liabilities | 45.72M | 53.07M | 30.31M | 37.31M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 3.48M | 14.49M | 27.84M | 37.56M |
| Common Par | 9.00K | 8.00K | 8.00K | 8.00K |
| Additional Paid In Capital | 359.01M | 351.25M | 341.70M | 321.07M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -355.54M | -336.78M | -313.88M | -283.59M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 5.00K | 6.00K | 10.00K | 81.00K |
| Total Capitalization | 3.48M | 14.49M | 28.35M | 38.22M |
| Total Equity | 3.48M | 14.49M | 27.84M | 37.56M |
| Total Liabilities & Stock Equity | 49.20M | 67.56M | 58.15M | 74.87M |
| Total Common Shares Outstanding | 87.55M | 87.05M | 86.76M | 82.03M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 87.41M | 86.87M | 83.43M | 78.33M |
| Diluted Weighted Shares Outstanding | 87.41M | 86.87M | 83.43M | 78.33M |
| Number of Employees | 106 | 131 | 127 | 171 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with DRRX
- Portfolio NameUser Type
- ProRobert Bruce
- Userdonellisor
- UserTrading
- Userbaustin002 Portfolio 1
- UserBarron's Research Reports 1...
- Userhititbig
- Userbv2
- UserFBSPANKEY Portfolio 1
- Usersandw1ch Portfolio 1
- Usermiguele4 Portfolio 1
Latest DRRX Headlines from TheStreet
- Business Highlights 06.24.11 | 06:06 pm
- Durect Stock Gaps Down On Today's Open (DRRX) 06.24.11 | 09:06 am
- Pfizer, Pain Therapeutics Drug Rejected by FDA 06.24.11 | 08:06 am
- 10 Stocks to Watch: Alcoa, BP 04.12.11 | 06:04 am
- Biotech Calendar: 2011 FDA Drug Approvals 02.22.11 | 07:02 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences 09.07.10 | 06:09 pm
- DURECT Corporation Q1 2010 Earnings Call Transcript 05.11.10 | 01:05 am
- Durect Says Pain Patch Met Goals In Clinical Study 03.16.09 | 02:03 pm
- Thursday's Winners & Losers: Durect 05.08.08 | 04:05 pm
- Health Winners & Losers: Barr 05.08.08 | 04:05 pm
Press Releases for DRRX
- DURECT Receives Back U.S. And Canadian Product Rights To POSIDUR⢠- PR Newswire 03.29.12 | 04:03 pm
- DURECT Corporation Invites You To Join Its Fourth Quarter 2011 Earnings Conference Call - PR Newswire 02.24.12 | 09:02 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 02.23.12 | 11:02 am
- DURECT To Present At The BIO CEO & Investor Conference - PR Newswire 02.07.12 | 12:02 pm
- DURECT Receives Back European Product Rights To POSIDUR⢠- PR Newswire 01.30.12 | 04:01 pm
- DURECT Announces Top-line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial) - PR Newswire 01.05.12 | 04:01 pm
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 11.07.11 | 08:11 am
- DURECT Corporation Invites You To Join Its Third Quarter 2011 Earnings Conference Call - PR Newswire 10.26.11 | 05:10 pm
- DURECT Completes Enrollment In Pivotal U.S. Phase III Trial For POSIDUR® (BESST) - PR Newswire 09.06.11 | 07:09 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 08.31.11 | 04:08 pm
Partner Headlines for DRRX
- Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT - Benzinga 03.01.12 | 04:03 pm
- DURECT Announces Top-line Data from BESST; Did Not Reach Statistical Significance - Benzinga 01.05.12 | 04:01 pm
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
- Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX) - Benzinga 08.05.10 | 09:08 am
- FDA Clears Hospira's Generic Drug - Analyst Blog - Zacks 06.25.10 | 01:06 pm
- UPDATE 1-Durect's pain drug shows mixed results in EU trial - Reuters 06.16.10 | 05:06 pm
- King Advances Pain Candidate - Analyst Blog - Zacks 04.08.10 | 06:04 pm
